← Back to Search

Antibiotic

Infection needing cefazolin for Pharmacokinetics

Phase 1
Waitlist Available
Research Sponsored by Drexel University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72-96 hours
Awards & highlights

Study Summary

This trial is testing the safety of adding cefazolin to CRRT solution and whether it results in therapeutic cefazolin concentrations in patients.

Eligible Conditions
  • Pharmacokinetics
  • Kidney Dialysis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72-96 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72-96 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cefazolin serum levels

Trial Design

3Treatment groups
Experimental Treatment
Group I: No infectionExperimental Treatment1 Intervention
c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
Group II: Infection not needing cefazolinExperimental Treatment1 Intervention
b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
Group III: Infection needing cefazolinExperimental Treatment1 Intervention
a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cefazolin
FDA approved

Find a Location

Who is running the clinical trial?

Drexel UniversityLead Sponsor
150 Previous Clinical Trials
47,649 Total Patients Enrolled
The Center for Pediatric PharmacotherapyUNKNOWN
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top